期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 28, 期 1, 页码 27-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2013.10.005
关键词
CD30; Reed-Sternberg; Monoclonal antibody; Antibody-drug conjugate
Hodgkin lymphoma (HL) is a relatively rare but highly curable human cancer. Because very few patients relapse and will require subsequent therapy, new drug development for HL has not been seen as a high priority by the pharmaceutical industry. Brentuximab vedotin, an antibody-drug conjugate that targets CD30 receptors, became the first drug to be approved by regulatory agencies for the treatment of HL in more than 30 years. This review summarizes the current and future directions of incorporating brentuximab vedotin in the management of patients with HL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据